Simmons Bank decreased its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 2.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,515 shares of the pharmaceutical company’s stock after selling 850 shares during the quarter. Simmons Bank’s holdings in GlaxoSmithKline PLC were worth $1,358,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of GSK. Russell Investments Group Ltd. bought a new position in shares of GlaxoSmithKline PLC during the 1st quarter worth $578,000. Independent Advisor Alliance grew its position in shares of GlaxoSmithKline PLC by 20.4% during the 1st quarter. Independent Advisor Alliance now owns 7,491 shares of the pharmaceutical company’s stock worth $314,000 after buying an additional 1,268 shares in the last quarter. Dixon Hubard Feinour & Brown Inc. VA bought a new position in shares of GlaxoSmithKline PLC during the 1st quarter worth $212,000. Premier Asset Managment LLC grew its position in shares of GlaxoSmithKline PLC by 10.8% during the 1st quarter. Premier Asset Managment LLC now owns 31,220 shares of the pharmaceutical company’s stock worth $1,316,000 after buying an additional 3,050 shares in the last quarter. Finally, 1st Global Advisors Inc. bought a new position in shares of GlaxoSmithKline PLC during the 1st quarter worth $221,000. 9.28% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/10/08/simmons-bank-sells-850-shares-of-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline PLC (NYSE GSK) traded down 0.12% during midday trading on Friday, reaching $40.61. The company’s stock had a trading volume of 2,771,814 shares. The firm has a market capitalization of $99.25 billion, a PE ratio of 39.35 and a beta of 1.03. The stock’s 50-day moving average price is $40.07 and its 200 day moving average price is $41.64. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.54.
GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The firm had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a yield of 4.84%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is presently 197.00%.
A number of research firms have recently issued reports on GSK. Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. TheStreet downgraded GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Argus reissued a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Tuesday, July 18th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, September 14th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $44.67.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.